Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it down for ...

Crispr (CRSP) has yet to generate any product sales from Casgevy. The FDA approved the sickle cell disease therapy in December as the first gene editing therapy in the U.S. However, its ...

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. The Biden Administration announced this week that the manufacturers of ...

Vertex Pharmaceuticals and CRISPR Therapeutics have scored another regulatory approval for Casgevy (exagamglogene autotemcel) after the European Commission granted conditional marketing ...

Its first treatment, Casgevy, earned approval from the Food and Drug Administration (FDA) to treat sickle cell disease in December 2023. Last January, the FDA approved Casgevy again to treat ...

Vertex offers up to $70,000 in fertility services assistance for patients undergoing Casgevy treatment. HHS claims Vertex’s program incentivizes patients to choose its gene therapy over competitors.

The newest gene therapy treatment, Casgevy, treats sick cell disease and transfusion-dependent beta thalassemia. Its addition means that CHLA provides the most cell and gene therapy treatments for ...

The company has just one product on the market, Casgevy, which treats transfusion-dependent beta-thalassemia and sickle cell disease, two rare blood disorders. Casgevy has been on the market for a ...

CRISPR Therapeutics stock slipped in November following its third-quarter report. Casgevy, a once-and-done treatment for sickle cell disease and beta-thalassemia, earned FDA approval last December ...